MENU
+Compare
ATHE
Stock ticker: NASDAQ
AS OF
Sep 25 closing price
Price
$4.06
Change
-$0.33 (-7.52%)
Capitalization
78.93M

ATHE Alterity Therapeutics Limited Forecast, Technical & Fundamental Analysis

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules... Show more

Industry: #Biotechnology
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ATHE with price predictions
Sep 25, 2025

ATHE's RSI Oscillator dives into oversold zone

The RSI Oscillator for ATHE moved into overbought territory on September 25, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

ATHE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 74 cases where ATHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ATHE as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ATHE moved below its 50-day moving average on September 11, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ATHE crossed bearishly below the 50-day moving average on September 16, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATHE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATHE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.630) is normal, around the industry mean (19.714). P/E Ratio (0.000) is within average values for comparable stocks, (54.201). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.145). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (346.197).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATHE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of therapeutic drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
350 Collins Street
Phone
+61 393494906
Employees
11
Web
https://www.alteritytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIPG0.02N/A
N/A
AI TECHNOLOGY GROUP INC.
BFNH0.81N/A
N/A
BioForce Nanosciences Holdings, Inc.
WLWHY3.03N/A
N/A
Woolworths Holdings Ltd.
SYIEF86.14-0.40
-0.47%
Symrise Ag
ECRAF1.09-0.01
-0.91%
ECORA RESOURCES PLC

ATHE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHE
1D Price
Change %
ATHE100%
-7.56%
EYPT - ATHE
54%
Loosely correlated
-6.32%
SLDB - ATHE
38%
Loosely correlated
-5.13%
TECX - ATHE
35%
Loosely correlated
-1.87%
GHRS - ATHE
31%
Poorly correlated
-3.67%
CVM - ATHE
29%
Poorly correlated
-5.23%
More